The Centers for Disease Control and Prevention made substantive changes to its coronavirus guidance on Aug. 11, citing protections that most Americans have from the virus through vaccinations and boosters or previous infection. The changes include dropping the 6-foot standard in social distancing and the guideline for unvaccinated people without symptoms or a positive test […] The post As CDC loosens COVID guidelines, Allegheny County transmission rate is medium appeared first on PublicSource. PublicSource is a nonprofit news organization serving the Pittsburgh region. Visit www.publicsource.org to read more.
Humboldt County Public Health reported today eight new hospitalizations including a resident in their 40s, two in their 50s, three in their 60s, one in their 70s and one aged 80 or older. No new deaths were reported. An additional 309 confirmed positive cases of COVID-19 were announced as well...
A COVID-vaccine maker received $1.6 billion in Operation Warp Speed funding. It’s administered just 7,300 shots in the U.S.
Novavax slashed its revenue forecast in half owing to sluggish demand for its new COVID shot. After so much hype, it turns out vaccine manufacturer Novavax’s long-awaited COVID jab hit the market far too late. In its second-quarter earnings on Monday, Novavax announced sales of just $186 million for...
SIOUX FALLS, S.D. (KELO) — The COVID-19 death toll has gone up by 10 in South Dakota from the previous week. According to Wednesday’s update to the South Dakota Department of Health COVID-19 dashboard, 2,973 people have died during the pandemic, up from 2,963 the previous week. The new deaths were seven men and three women in the following age groups: 50-59 (1), 70-79 (4), 80+ (5). New deaths were reported in the following counties: Beadle, Brookings, Brown (2), Clay, Codington, Custer, Minnehaha, Pennington and Perkins.
Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics is the latest sign that cash-flush drug makers are ready to make some deals.
YOU MAY ALSO LIKE
A powerful new weapon may soon be coming to fight against Lyme disease as Pfizer begins a late-phase clinical trial for a new vaccine, some say it isn't enough.
The Suburban Times
Tacoma-Pierce County Health Department announcement. Pierce County remains in Centers for Disease Control and Prevention’s low COVID-19 community level. Our COVID-19 7-day hospitalization rate dropped more than 50% from last week and we’ve seen a drop in case rate as well. At the low level, CDC recommends you:
Todos Medical Inc.(OTCMKTS: TOMDF) has been extremely resourceful in the past couple of weeks winning the Monkeypox testing business through a focused customer outreach. On Monday they announced their first two contracts for Monkeypox testing. Proactive Investors did an interview with the CEO and revealed a very deliberate plan of action to have the test validated within a couple of weeks and onboard new and existing customers. Their plan was to canvas the New York and New Jersey locations and get reference agreements from the small testing labs that have the demand but don’t want to scale up the infrastructure for Monkeypox. Todos’ Provista Diagnostics laboratory is highly automated and can accept this kind of demand.
New research, published in Frontiers in Immunology and conducted by the Tisch Multiple Sclerosis Research Center of New York, suggests that multiple sclerosis (MS) patients receiving anti-CD20 therapy saw strong T-cell activation after receiving two doses of the COVID-19 vaccine. Anti-CD20 therapies cause B-cell depletion, and MS patients receiving these therapies are considered especially vulnerable to COVID-19 due to their lower production of antibodies. This research advances the analysis of T-cell responses, particularly for MS patients, and underscores the larger need to better understand T-cell responses among immunocompromised individuals. Further research advancements may have potential implications for future vaccine designs and applications.
The EU's medicines watchdog said Wednesday it aims to approve this autumn a Pfizer/BioNTech COVID vaccine adapted for two fast-spreading subvariants of the Omicron strain. Milder but more infectious than earlier types of the COVID virus, the BA.4 and BA.5 types have helped to drive a wave of new cases of the disease in Europe and the United States.
STATEN ISLAND, N.Y. — Vaccine makers Pfizer and Valneva SE announced the start of phase 3 clinical studies for their Lyme disease vaccine, the only immunization currently in development to combat the tick-borne disease. The companies are planning to enroll around 6,000 people ages 5 and older in 50...
The number of COVID-19 tests performed, the number of positive cases, and the positivity rate all rose during the week of Aug. 1-7, according to LincolnHealth spokesperson John Martins. There were 247 tests performed and 35 positive cases identified in the past week, compared to 218 with 28 positives the...
On Monday, Pfizer and French drug maker Valneva announced they are in phase three of developing a vaccine against Lyme disease. The vaccine candidate has been named VLA15 and is the only Lyme disease vaccine in development. It is still being tested for quality, safety, and efficacy. “With increasing global...
VIENNA -- Patients with non-squamous metastatic non-small cell lung cancer (NSCLC) who had tumor mutations associated with poor prognosis experienced meaningful improvements in survival when treated with a first-line regimen of two immunotherapies plus chemotherapy, a researcher reported. An exploratory analysis from the POSEIDON trial showed a trend for an...
What is the COVID-19 situation like in Florida?
The Michigan Department of Health and Human Services reports confirmed cases averaged 2,305 per day.
Duncansville, Pa. — Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years -- in hopes of better fighting the tick-borne threat. Lyme is a growing problem, with cases rising and warming weather helping ticks expand...
GSK plc (NYSE:GSK) and Sanofi (SNY) (OTCPK:SNYNF) (GCVRX), joint developers of a COVID-19 vaccine, traded sharply lower on Wednesday on above-average volume amid concerns over the disappointing Q2 release from the newest vaccine entrant Novavax (NVAX). With a decline of ~9%, Sanofi (SNY) ADRs have approached a 52-week low while...
Aug 9 (Reuters) - Shares of U.S. vaccine maker Novavax (NVAX.O) fell about 30% on Tuesday after it cut its annual revenue forecast by half over falling demand for its COVID-19 shot from low- and middle-income nations.